Switch theme
Sign up to access all valuation multiples
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
1992
820
LTM Revenue $625M
LTM EBITDA $266M
$3.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hualan Biological Engineering has a last 12-month revenue of $625M and a last 12-month EBITDA of $266M.
In the most recent fiscal year, Hualan Biological Engineering achieved revenue of $603M and an EBITDA of $222M.
Hualan Biological Engineering expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hualan Biological Engineering valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $736M | $603M | XXX | XXX | XXX |
| Gross Profit | $411M | $512M | XXX | XXX | XXX |
| Gross Margin | 56% | 85% | XXX | XXX | XXX |
| EBITDA | $324M | $222M | XXX | XXX | XXX |
| EBITDA Margin | 44% | 37% | XXX | XXX | XXX |
| Net Profit | $148M | $204M | XXX | XXX | XXX |
| Net Margin | 20% | 34% | XXX | XXX | XXX |
| Net Debt | $0.2M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hualan Biological Engineering's stock price is CNY 17 (or $2).
Hualan Biological Engineering has current market cap of CNY 30.3B (or $4.2B), and EV of CNY 27.9B (or $3.8B).
See Hualan Biological Engineering trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.8B | $4.2B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hualan Biological Engineering has market cap of $4.2B and EV of $3.8B.
Hualan Biological Engineering's trades at 6.2x LTM EV/Revenue multiple, and 14.5x LTM EBITDA.
Analysts estimate Hualan Biological Engineering's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hualan Biological Engineering and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.8B | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | 17.3x | XXX | XXX | XXX |
| P/E | 27.8x | XXX | XXX | XXX |
| P/E/Growth | 1.6x | XXX | XXX | XXX |
| EV/FCF | 34.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHualan Biological Engineering's NTM/LTM revenue growth is 12%
Hualan Biological Engineering's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Hualan Biological Engineering's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hualan Biological Engineering's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hualan Biological Engineering and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 49% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hualan Biological Engineering acquired XXX companies to date.
Last acquisition by Hualan Biological Engineering was XXXXXXXX, XXXXX XXXXX XXXXXX . Hualan Biological Engineering acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hualan Biological Engineering founded? | Hualan Biological Engineering was founded in 1992. |
| Where is Hualan Biological Engineering headquartered? | Hualan Biological Engineering is headquartered in China. |
| How many employees does Hualan Biological Engineering have? | As of today, Hualan Biological Engineering has 820 employees. |
| Is Hualan Biological Engineering publicy listed? | Yes, Hualan Biological Engineering is a public company listed on SHE. |
| What is the stock symbol of Hualan Biological Engineering? | Hualan Biological Engineering trades under 002007 ticker. |
| When did Hualan Biological Engineering go public? | Hualan Biological Engineering went public in 2004. |
| Who are competitors of Hualan Biological Engineering? | Similar companies to Hualan Biological Engineering include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hualan Biological Engineering? | Hualan Biological Engineering's current market cap is $4.2B |
| What is the current revenue of Hualan Biological Engineering? | Hualan Biological Engineering's last 12-month revenue is $625M. |
| What is the current EBITDA of Hualan Biological Engineering? | Hualan Biological Engineering's last 12-month EBITDA is $266M. |
| What is the current EV/Revenue multiple of Hualan Biological Engineering? | Current revenue multiple of Hualan Biological Engineering is 6.2x. |
| What is the current EV/EBITDA multiple of Hualan Biological Engineering? | Current EBITDA multiple of Hualan Biological Engineering is 14.5x. |
| What is the current revenue growth of Hualan Biological Engineering? | Hualan Biological Engineering revenue growth between 2023 and 2024 was -18%. |
| Is Hualan Biological Engineering profitable? | Yes, Hualan Biological Engineering is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
